
Hans-Peter Sinn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8539224/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients. Annals of Surgical Oncology, 2022, 29, 1076-1084.	1.5	15
2	Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. Annals of Surgery, 2022, 275, 576-581.	4.2	38
3	ASO Visual Abstract: Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment to Reliably Exclude Residual Cancer in Breast Cancer Patients. Annals of Surgical Oncology, 2022, 29, 1085-1086.	1.5	0
4	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	2.8	8
5	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
6	Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. Nature Cancer, 2022, 3, 486-504.	13.2	35
7	Sex chromosome DSD individuals with mosaic 45,X0 and aberrant Y chromosomes in 46,XY cells: distinct gender phenotypes and germ cell tumour risks [§] . Systems Biology in Reproductive Medicine, 2022, 68, 247-257.	2.1	3
8	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care, 2022, 17, 403-420.	1.4	43
9	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care, 2022, 17, 421-429.	1.4	9
10	A multicentre analytical comparison study of interâ€reader and interâ€assay agreement of four programmed deathâ€ligand 1 immunohistochemistry assays for scoring in tripleâ€negative breast cancer. Histopathology, 2021, 78, 567-577.	2.9	23
11	CaM Kinase II-δ Is Required for Diabetic Hyperglycemia and Retinopathy but Not Nephropathy. Diabetes, 2021, 70, 616-626.	0.6	9
12	Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients. European Journal of Radiology, 2021, 135, 109468.	2.6	23
13	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	7.0	27
14	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.	3.0	20
15	Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapyâ<†. Annals of Oncology, 2021, 32, 500-511.	1.2	9
16	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Modern Pathology, 2021, 34, 1558-1569.	5.5	28
17	uPAâ€PAIâ€1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. EMBO Molecular Medicine, 2021, 13, e13110.	6.9	5
18	66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto. Annals of Oncology, 2021, 32, S49-S50.	1.2	0

#	Article	IF	CITATIONS
19	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
20	JUNB suppresses distant metastasis by influencing the initial metastatic stage. Clinical and Experimental Metastasis, 2021, 38, 411-423.	3.3	5
21	Breast cancer characteristics and surgery among women with Liâ€Fraumeni syndrome in Germany—A retrospective cohort study. Cancer Medicine, 2021, 10, 7747-7758.	2.8	7
22	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care, 2021, 16, 228-235.	1.4	20
23	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care, 2021, 16, 214-227.	1.4	51
24	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Und Frauenheilkunde, 2021, 81, 1112-1120.	1.8	17
25	Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. Breast Cancer Research and Treatment, 2020, 179, 425-433.	2.5	16
26	Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Annals of Oncology, 2020, 31, 61-71.	1.2	119
27	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 97-104.	2.5	29
28	Chromothripsis in Human Breast Cancer. Cancer Research, 2020, 80, 4918-4931.	0.9	11
29	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	7.0	41
30	Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A–Type Breast Cancer. JCO Precision Oncology, 2020, 4, 848-859.	3.0	7
31	MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS ONE, 2020, 15, e0238021.	2.5	8
32	Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples. International Journal of Molecular Sciences, 2020, 21, 6407.	4.1	18
33	Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?. European Journal of Radiology, 2020, 128, 109025.	2.6	14
34	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	1.2	85
35	Ultra-High- <i>b</i> -Value Kurtosis Imaging for Noninvasive Tissue Characterization of Ovarian Lesions. Radiology, 2020, 296, 358-369.	7.3	10
36	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43

#	Article	IF	CITATIONS
37	Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 1604.	3.7	63
38	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
39	Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nature Communications, 2020, 11, 1494.	12.8	115
40	Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 137-144.	2.5	19
41	Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle. Diagnostics, 2020, 10, 369.	2.6	2
42	Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATAâ€binding protein 3 in nonâ€smallâ€cell lung cancer. Histopathology, 2020, 77, 900-914.	2.9	6
43	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Annals of Oncology, 2020, 31, 1216-1222.	1.2	128
44	Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany. Breast, 2020, 49, 246-253.	2.2	2
45	Endometrial stromal sarcomas with <i>BCOR</i> â€rearrangement harbor <i>MDM2</i> amplifications. Journal of Pathology: Clinical Research, 2020, 6, 178-184.	3.0	32
46	The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 2161.	4.1	6
47	Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. Cancer Research, 2020, 80, GS5-03-GS5-03.	0.9	9
48	Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial. , 2020, , .		0
49	Abstract P6-10-04: Landscape of immune-cell signatures in early high-risk breast cancer (BC) reveals clinically-relevant enrichment of immune subpopulations. , 2020, , .		0
50	Impact of mRNA-assessed intrinsic subtype conversion between primary and metastatic breast cancer on survival. , 2020, 80, .		0
51	Diagnostic accuracy and clinical utility of axillary ultrasound in the evaluation of axillary lymph node status in early breast cancer patients. , 2020, 80, .		0
52	Receptor discordance between primary tumor and metastasis influences CTC-status. , 2020, 80, .		0
53	IgG4â€related sclerosing mastitis in a 49â€yearâ€old patient with multiple, tumorâ€like nodules—Diagnostic accuracy of core needle biopsy. Breast Journal, 2019, 25, 1251-1253.	1.0	9
54	Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype. Annals of Surgical Oncology, 2019, 26, 4381-4389.	1.5	18

#	Article	IF	CITATIONS
55	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care, 2019, 14, 247-255.	1.4	32
56	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care, 2019, 14, 224-245.	1.4	72
57	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
58	Author's reply to: Comparing the performance of gene expression assays in breast cancer. International Journal of Cancer, 2019, 145, 1163-1164.	5.1	0
59	Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. Cancers, 2019, 11, 342.	3.7	8
60	Gonadoblastoma Y locus genes expressed in germ cells of individuals with dysgenetic gonads and a Y chromosome in their karyotypes include <i>DDX3Y</i> and <i>TSPY</i> . Human Reproduction, 2019, 34, 770-779.	0.9	21
61	Renal Tubular Dysgenesis in a Case of Fetus Acardius Amorphus. Case Reports in Pathology, 2019, 2019, 1-11.	0.3	1
62	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care, 2019, 14, 53-59.	1.4	13
63	Summary of headâ€ŧoâ€head comparisons of patient risk classifications by the 21â€gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. International Journal of Cancer, 2019, 145, 882-893.	5.1	32
64	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Research and Treatment, 2019, 173, 155-165.	2.5	11
65	Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial Journal of Clinical Oncology, 2019, 37, 509-509.	1.6	10
66	Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial. Cancer Research, 2019, 79, PD2-07-PD2-07.	0.9	7
67	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
68	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. International Journal of Cancer, 2018, 143, 746-757.	5.1	19
69	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	7.7	298
70	Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years. Modern Pathology, 2018, 31, 607-615.	5.5	25
71	Complement Activation in Peritoneal Dialysis–Induced Arteriolopathy. Journal of the American Society of Nephrology: JASN, 2018, 29, 268-282.	6.1	45
72	Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy. Annals of Surgery, 2018, 268, e60-e61.	4.2	3

#	Article	lF	CITATIONS
73	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	10.7	1,327
74	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1056-1088.	1.8	69
75	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Und Frauenheilkunde. 2018. 78. 927-948.	1.8	59
76	Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. EMBO Molecular Medicine, 2018, 10, .	6.9	77
77	The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene, 2018, 37, 4750-4768.	5.9	111
78	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
79	Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study. BMC Cancer, 2018, 18, 616.	2.6	47
80	RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC Cancer, 2018, 18, 851.	2.6	32
81	Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer, 2017, 17, 124.	2.6	62
82	Intrinsic subtypes and risk scores in ER+/HER2-Breast Cancer: a comparison of Prosigna and OncotypeDX risk categories with Ki67. Breast, 2017, 32, S105.	2.2	2
83	The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer. Oncogene, 2017, 36, 4124-4134.	5.9	60
84	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
85	Genistein and enterolactone in relation to Kiâ€67 expression and HER2 status in postmenopausal breast cancer patients. Molecular Nutrition and Food Research, 2017, 61, 1700449.	3.3	13
86	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2017, 77, 633-644.	1.8	28
87	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017. Breast Care, 2017, 12, 172-183.	1.4	17
88	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017. Breast Care, 2017, 12, 184-191.	1.4	11
89	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Research, 2017, 19, 55.	5.0	29
90	Targeted nextâ€generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes and Cancer, 2017, 56, 255-265.	2.8	21

#	Article	IF	CITATIONS
91	Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Modern Pathology, 2017, 30, 217-226.	5.5	29
92	Identification of a characteristic vascular belt zone in human colorectal cancer. PLoS ONE, 2017, 12, e0171378.	2.5	14
93	Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget, 2017, 8, 51416-51428.	1.8	16
94	Abstract P2-05-25: Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. , 2017, , .		0
95	Mutations in genes encoding <scp>Pl3Kâ€AKT</scp> and <scp>MAPK</scp> signaling define anogenital papillary hidradenoma. Genes Chromosomes and Cancer, 2016, 55, 113-119.	2.8	29
96	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	5.5	230
97	Lean Umbilical Cord – a Case Report. Geburtshilfe Und Frauenheilkunde, 2016, 76, 1186-1188.	1.8	1
98	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer, 2016, 16, 734.	2.6	126
99	Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Research and Treatment, 2016, 160, 491-499.	2.5	54
100	Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?. European Journal of Cancer, 2016, 69, 142-150.	2.8	59
101	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	5.0	56
102	Highâ€ŧhroughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2016, 2, 138-153.	3.0	19
103	Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. Annals of Surgical Oncology, 2016, 23, 757-766.	1.5	15
104	Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery?. Annals of Surgical Oncology, 2016, 23, 1831-1837.	1.5	25
105	Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?. Annals of Surgical Oncology, 2016, 23, 789-795.	1.5	84
106	Role of <i>TP53</i> mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698.	1.8	50
107	Premalignant and Malignant Breast Pathology. , 2016, , 179-194.		0
108	Abstract P1-07-12: Prognosis of clinico-pathological breast cancer subtypes in routine clinical care. ,		0

2016,,.

#	Article	IF	CITATIONS
109	Abstract P1-03-05: SPARC expression in primary metastatic breast cancer. , 2016, , .		0
110	Predictive value of ultra-high ESR1 mRNA expression in early breast cancer Journal of Clinical Oncology, 2016, 34, e12045-e12045.	1.6	0
111	Distribution of <i>MED12</i> mutations in fibroadenomas and phyllodes tumors of the breast—implications for tumor biology and pathological diagnosis. Genes Chromosomes and Cancer, 2015, 54, 444-452.	2.8	55
112	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers. Journal of Clinical Oncology, 2015, 33, 983-991.	1.6	863
113	WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. Pathology Research and Practice, 2015, 211, 109-116.	2.3	11
114	Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer. Cancer Research, 2015, 75, 720-731.	0.9	36
115	S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer. Experimental and Molecular Pathology, 2015, 99, 180-187.	2.1	21
116	Breast Cancers with a <i>BRCA1</i> -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy. Clinical Cancer Research, 2015, 21, 763-770.	7.0	34
117	Predictors of Residual Tumor in Breast-Conserving Therapy. Annals of Surgical Oncology, 2015, 22, 451-458.	1.5	12
118	Abstract P5-10-17: Evaluation of PgR status by immunohistochemistry may be inferior to PgR results by Oncotype DX for assessing the recurrence risk in ER+/HER2- breast cancer with low or intermediate tumor proliferation. , 2015, , .		0
119	Assessing HER2 testing quality in breast cancer (BC): Variables that influence HER2-positivity from a large, multicenter, observational study in Germany Journal of Clinical Oncology, 2015, 33, 11062-11062.	1.6	1
120	Differentiation and histogenesis of syringomatous tumour of the nipple and lowâ€grade adenosquamous carcinoma: evidence for a common origin. Histopathology, 2014, 65, 9-23.	2.9	41
121	Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1034-1046.	1.7	18
122	Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk. Archives of Gynecology and Obstetrics, 2014, 289, 1079-1085.	1.7	2
123	Comparison of molecular abnormalities in vulvar and vaginal melanomas. Modern Pathology, 2014, 27, 1386-1393.	5.5	70
124	Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. Cancer Epidemiology, 2014, 38, 419-426.	1.9	19
125	<i>PIK3CA</i> Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3212-3220.	1.6	231
126	Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer. Translational Proteomics, 2014, 2, 52-59.	1.2	19

#	Article	IF	CITATIONS
127	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget, 2014, 5, 8147-8160.	1.8	83
128	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	1.8	58
129	Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC) Journal of Clinical Oncology, 2014, 32, e12009-e12009.	1.6	0
130	Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Research, 2014, 34, 6609-15.	1.1	32
131	Giant struma ovarii. Archives of Gynecology and Obstetrics, 2013, 287, 399-400.	1.7	2
132	Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 507-513.	2.8	63
133	Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss. Modern Pathology, 2013, 26, 1161-1171.	5.5	47
134	Omission of Axillary Dissection According to ACOSOG Z0011: Impact on Adjuvant Treatment Recommendations. Annals of Surgical Oncology, 2013, 20, 1538-1544.	1.5	23
135	Circulating Fibronectin Controls Tumor Growth. Neoplasia, 2013, 15, 925-IN24.	5.3	55
136	Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. Breast, 2013, 22, 986-992.	2.2	35
137	Prediction of underestimated invasiveness in patients with ductal carcinoma inÂsitu of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. Breast, 2013, 22, 537-542.	2.2	48
138	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 2013, 31, 539-544.	17.5	920
139	A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care, 2013, 8, 149-154.	1.4	280
140	Effects of mTOR Inhibition On IR/IGF-1R Signalling in PIK3CA-Mutated, Tamoxifen Resistant Breast Cancer. Annals of Oncology, 2013, 24, iii25.	1.2	0
141	Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. Geburtshilfe Und Frauenheilkunde, 2013, 73, 932-940.	1.8	55
142	Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERαâ€positive breast cancer. International Journal of Cancer, 2013, 132, 2714-2719.	5.1	7
143	Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Longâ€ŧerm survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. International Journal of Cancer, 2013, 133, 1006-1015.	5.1	12
144	Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. PLoS ONE, 2013, 8, e58483.	2.5	59

#	Article	IF	CITATIONS
145	Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer. PLoS ONE, 2013, 8, e76729.	2.5	112
146	Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66). , 2013, , .		16
147	Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies. Cancer Research, 2013, 73, S4-06-S4-06.	0.9	8
148	Abstract P1-08-07: High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. , 2013, , .		0
149	Abstract P1-08-15: Prognostic value of five different histologic scoring systems for tumor regression after neoadjuvant chemotherapy of breast cancer in luminal type breast cancer. , 2013, , .		Ο
150	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
151	Interdisciplinary Consensus Recommendations for the use of Vacuum-Assisted Breast Biopsy under Sonographic Guidance: First update 2012. Ultraschall in Der Medizin, 2012, 33, 366-371.	1.5	51
152	Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene, 2012, 31, 4599-4608.	5.9	84
153	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. Breast Care, 2012, 7, 364-369.	1.4	11
154	Transitions Between Flat Epithelial Atypia and Low-grade Ductal Carcinoma In Situ of the Breast. American Journal of Surgical Pathology, 2012, 36, 1247-1252.	3.7	13
155	847 Identification of a Biomarker Signature to Predict the Need for Chemotherapy in Patients With Hormone Receptor Positive Breast Cancer. European Journal of Cancer, 2012, 48, S203-S204.	2.8	0
156	Genomeâ€wide methylation screen in lowâ€grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB Journal, 2012, 26, 4937-4950.	0.5	84
157	Predictors of resectability in breast-conserving therapy. Archives of Gynecology and Obstetrics, 2012, 286, 1023-1031.	1.7	7
158	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
159	CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Research and Treatment, 2012, 132, 819-831.	2.5	21
160	Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. Breast, 2012, 21, 303-308.	2.2	42
161	Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. , 2012, , .		2
162	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596

#	Article	IF	CITATIONS
163	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
164	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
165	Automatic Tumor-Stroma Separation in Fluorescence TMAs Enables the Quantitative High-Throughput Analysis of Multiple Cancer Biomarkers. PLoS ONE, 2011, 6, e28048.	2.5	13
166	Triple-Negative Breast Cancer: Clinical and Histological Correlations. Breast Care, 2011, 6, 273-278.	1.4	39
167	Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients. Cancer Immunology, Immunotherapy, 2011, 60, 401-411.	4.2	4
168	Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains—Induction of a Strong Immune Response against Breast Tumor Tissues. Angewandte Chemie - International Edition, 2011, 50, 9977-9981.	13.8	90
169	Variable expression of the Fragile X Mental Retardation 1 (FMR1) gene in patients with premature ovarian failure syndrome is not dependent on number of (CGG)n triplets in exon 1. Human Reproduction, 2011, 26, 1241-1251.	0.9	36
170	High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive for BRCA1- and BRCA2-Deficient Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4586-4588.	1.6	17
171	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.9	109
172	Reply to L. Ozretić et al. Journal of Clinical Oncology, 2011, 29, 4588-4589.	1.6	1
173	A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Annals of Oncology, 2011, 22, 609-617.	1.2	18
174	Basoluminal and luminal phenotypes in triple-negative breast cancer: Immunohistochemical profiling and survival Journal of Clinical Oncology, 2011, 29, 1098-1098.	1.6	0
175	Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 741-747.	2.8	31
176	Robust gridding of TMAs after wholeâ€slide imaging using template matching. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 1169-1176.	1.5	11
177	Simulation of heat transfer in zone plate optics irradiated by X-ray free electron laser radiation. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2010, 621, 620-626.	1.6	11
178	FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Annals of Oncology, 2010, 21, 1636-1642.	1.2	31
179	Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies. Breast Care, 2010, 5, 218-226.	1.4	24
180	Invasive ductal breast cancer within a malignant phyllodes tumor: case report and assessment of clonality. Human Pathology, 2010, 41, 293-296.	2.0	21

#	Article	IF	CITATIONS
181	Reduction of CD44+/CD24â^² breast cancer cells by conventional cytotoxic chemotherapy. Human Pathology, 2010, 41, 574-581.	2.0	32
182	Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer Journal of Clinical Oncology, 2010, 28, 543-543.	1.6	9
183	Invasive Tubular Carcinoma of the Breast Frequently is Clonally Related to Flat Epithelial Atypia and Low-grade Ductal Carcinoma In Situ. American Journal of Surgical Pathology, 2009, 33, 1646-1653.	3.7	48
184	Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer–Specific Immune Responses and Their Correlation to Prognosis. Cancer Research, 2009, 69, 8420-8428.	0.9	55
185	Estrogen-Related Receptor α Expression and Function Is Associated with the Transcriptional Coregulator AIB1 in Breast Carcinoma. Cancer Research, 2009, 69, 5186-5193.	0.9	28
186	0178 Results of clinical endpoints of a randomized phase II trial with doxorubicin + pemetrexed followed by docetaxel versus doxorubicin + cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer. Breast, 2009, 18, S63.	2.2	0
187	Breast cancer precursors: lessons learned from molecular genetics. Journal of Molecular Medicine, 2009, 87, 113-115.	3.9	14
188	Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. Journal of Molecular Medicine, 2009, 87, 995-1007.	3.9	72
189	Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer Immunology, Immunotherapy, 2009, 58, 887-900.	4.2	46
190	The role of molecular analysis in breast cancer. Pathology, 2009, 41, 77-88.	0.6	44
191	Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Research and Treatment, 2008, 107, 331-335.	2.5	50
192	Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Research, 2008, 10, R30.	5.0	96
193	The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. International Journal of Cancer, 2008, 122, 1207-1213.	5.1	146
194	Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. Annals of Oncology, 2008, 19, 1698-1705.	1.2	11
195	Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. Journal of Clinical Pathology, 2008, 61, 1034-1037.	2.0	24
196	Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-Cancer Drugs, 2007, 18, 477-485.	1.4	75
197	35 Tumor endothelial marker 1 (TEM1, endosialin) is expressed in functional and morphological distinct trophoblast cells in human and mouse placenta. Thrombosis Research, 2007, 119, S106.	1.7	0
198	Doxorubicin/Pemetrexed Followed by Docetaxel Versus Doxorubicin/Cyclophosphamide Followed by Docetaxel as Neoadjuvant Treatment for Early-Stage Breast Cancer: A Randomized Phase II Trial. Clinical Breast Cancer, 2007, 7, 555-558.	2.4	6

#	Article	IF	CITATIONS
199	Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. American Journal of Obstetrics and Gynecology, 2007, 196, 342.e1-342.e9.	1.3	35
200	HER2 overexpression is associated with shorter disease-free survival (DFS) following neoadjuvant systemic therapy (NST) of primary breast cancer (PBC) patients with gemcitabine (G), epirubicin (E) and docetaxel (Doc). Journal of Clinical Oncology, 2007, 25, 11087-11087.	1.6	0
201	Oblimersen (O) in combination with docetaxel (T), adriamycin (A), and cyclophosphamide (C) as neoadjuvant systemic therapy (NST) in primary breast cancer (PBC): Final results of a multicentric phase I study. Journal of Clinical Oncology, 2007, 25, 11047-11047.	1.6	0
202	Comparison of immunohistological parameters in primary breast cancers and corresponding locoregional recurrences. Pathology Research and Practice, 2006, 202, 125-130.	2.3	2
203	Consensus recommendations for the use of vacuum-assisted breast biopsy under sonographic guidance. Gynecological Surgery, 2006, 3, 309-314.	0.9	2
204	Gene Expression Signature Predicting Pathologic Complete Response With Gemcitabine, Epirubicin, and Docetaxel in Primary Breast Cancer. Journal of Clinical Oncology, 2006, 24, 1839-1845.	1.6	146
205	c-myc Amplifications in primary breast carcinomas and their local recurrences. Journal of Clinical Pathology, 2006, 59, 424-4248.	2.0	49
206	Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. Anti-Cancer Drugs, 2005, 16, 1023-1028.	1.4	11
207	Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer. Breast, 2005, 14, 230-235.	2.2	10
208	Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 305-309.	2.8	12
209	Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor. Gynecological Endocrinology, 2005, 21, 138-141.	1.7	17
210	The role of early expression of inducible nitric oxide synthase in human breast cancer. European Journal of Cancer, 2005, 41, 265-271.	2.8	88
211	Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy. Annals of Oncology, 2004, 15, 1627-1632.	1.2	1
212	Prediction of the axillary lymph node status in mammary cancer on the basis of clinicopathological data and flow cytometry. Medical and Biological Engineering and Computing, 2004, 42, 733-739.	2.8	16
213	Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. European Journal of Cancer, 2004, 40, 2432-2438.	2.8	22
214	Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy. Anti-Cancer Drugs, 2004, 15, 127-135.	1.4	23
215	Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families. Hereditary Cancer in Clinical Practice, 2004, 2, 139.	1.5	2
216	CTCF Gene Mutations in Invasive Ductal Breast Cancer. Breast Cancer Research and Treatment, 2003, 80, 347-352.	2.5	38

#	Article	IF	CITATIONS
217	Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. European Radiology, 2003, 13, 80-87.	4.5	84
218	Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. International Journal of Cancer, 2003, 105, 444-453.	5.1	44
219	Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. International Journal of Cancer, 2003, 107, 346-352.	5.1	55
220	Breast cancer in young women (â‰ \$ 5 years): Genomic aberrations detected by comparative genomic hybridization. International Journal of Cancer, 2003, 107, 583-592.	5.1	54
221	Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. European Journal of Human Genetics, 2003, 11, 464-467.	2.8	21
222	Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. European Radiology, 2003, 13, 1213-1223.	4.5	112
223	International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. Journal of Clinical Oncology, 2003, 21, 2600-2608.	1.6	322
224	Prognosefaktoren bei der Planung organübergreifender Debulkingoperation und intraoperativer Strahlentherapie bei Beckenwandrezidiven gynĤologischer Karzinome. Geburtshilfe Und Frauenheilkunde, 2002, 62, 554-559.	1.8	1
225	Magnetic Resonance Imaging of Nude Mice With Heterotransplanted High-Grade Squamous Cell Carcinomas. Investigative Radiology, 2002, 37, 193-198.	6.2	25
226	Characteristics associated withlong-term progression-free survival following high-dose chemotherapyin metastatic breast cancer and influence of chemotherapy dose. Annals of Oncology, 2002, 13, 679-688.	1.2	10
227	Anti-p53 in Breast Cancer: Concordance of Different Assay Procedures and Association with p53 Antigen Expression. Oncology, 2002, 63, 297-305.	1.9	19
228	P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. International Journal of Cancer, 2002, 100, 290-296.	5.1	29
229	Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer, 2002, 95, 1191-1198.	4.1	70
230	Stem Cell Dose and Tumorbiologic Parameters as Prognostic Markers for Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy with Autologous Blood Stem Cell Support. Stem Cells, 2002, 20, 32-40.	3.2	8
231	C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2002, 74, 25-31.	2.5	41
232	Clinical response after two cycles is superior to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. European Journal of Cancer, 2002, 38, S107.	2.8	0
233	Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biology of Blood and Marrow Transplantation, 2001, 7, 332-342.	2.0	11
234	Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. Journal of Pathology, 2001, 195, 415-421.	4.5	112

#	Article	IF	CITATIONS
235	Prognostic value of codon 918 (ATG?ACG)RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. International Journal of Cancer, 2001, 95, 62-66.	5.1	127
236	Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. International Journal of Cancer, 2001, 93, 80-84.	5.1	34
237	Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Research and Treatment, 2000, 59, 185-192.	2.5	48
238	Stage IIa Cervix Carcinoma with Metastasis to the Heart: Report of a Case with Immunohistochemistry, Flow Cytometry, and Virology Findings. Gynecologic Oncology, 2000, 76, 133-138.	1.4	5
239	Prognostic value of cathepsin D in breast cancer. British Journal of Cancer, 1999, 79, 189-190.	6.4	35
240	Trypsinogen activation peptides (TAP) in peritoneal fluid as predictors of late histopathologic injury in necrotizing pancreatitis of the rat. Digestive Diseases and Sciences, 1999, 44, 823-829.	2.3	8
241	Pathophysiologic basis of contrast enhancement in breast tumors. Journal of Magnetic Resonance Imaging, 1999, 10, 260-266.	3.4	360
242	Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast. European Journal of Cancer, 1999, 35, S86.	2.8	0
243	Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. British Journal of Cancer, 1998, 78, 1661-1668.	6.4	88
244	Extensive and predominant in situ component in breast carcinoma: their influence on treatment results after breast-conserving therapy. European Journal of Cancer, 1998, 34, 646-653.	2.8	53
245	Cyclins and Breast Cancer. Oncology Research and Treatment, 1998, 21, 28-34.	1.2	1
246	Response to primary chemotherapy of breast cancer. European Journal of Cancer, 1997, 33, S147.	2.8	0
247	Benefits of various dextrans after delayed therapy in necrotizing pancreatitis of the rat. Intensive Care Medicine, 1996, 22, 1207-1213.	8.2	2
248	Laser-Induced Fluorescence Diagnosis and Photodynamic Therapy of Human Renal Cell Carcinoma. Urologia Internationalis, 1995, 55, 197-201.	1.3	6
249	Comparison of immunohistochemistry and RTâ€₽CR for detection of CD44vâ€expression, a new prognostic factor in human breast cancer. International Journal of Cancer, 1995, 60, 471-477.	5.1	149
250	Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Research and Treatment, 1995, 36, 307-313.	2.5	64
251	Hyperoncotic Dextran and Systemic Aprotinin in Necrotizing Rodent Pancreatitis. Scandinavian Journal of Gastroenterology, 1995, 30, 812-816.	1.5	21
252	CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, The, 1995, 345, 615-619.	13.7	344

#	Article	IF	CITATIONS
253	CD44 isoforms in prognosis of breast cancer. Lancet, The, 1995, 346, 502.	13.7	14
254	Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the walker carcinosarcoma 256 rat model. Journal of Bone and Mineral Research, 1995, 10, 7-16.	2.8	9
255	Relevance of CD44 Variant Epitopes for Diagnosis and Therapy of Human Breast Cancer. Contributions To Oncology / Beitrage Zur Onkologie, 1995, , 36-50.	0.1	0
256	Diagnosis and Surgical Treatment of Gastric Sarcoma. Oncology Research and Treatment, 1994, 17, 391-396.	1.2	2
257	Metastatic potential of small and minimally invasive breast carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 425, 237-41.	2.8	14
258	Effect ofN-methy-N′-nitro-N-nitrosoguanidine on carbohydrate profiles of non-metaplastic rat gastric mucosa. Journal of Cancer Research and Clinical Oncology, 1993, 119, 155-159.	2.5	0
259	Characterization of New Monoclonal Antibodies Directed Against Normal Human Exocrine Pancreas and Pancreatic Adenocarcinomas. Pancreas, 1993, 8, 279-288.	1.1	2
260	ROLE OF NATURAL KILLER CELLS IN THE PATHOGENESIS OF HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE. Transplantation, 1993, 56, 113-119.	1.0	27
261	Chromogranin A as Tumor Marker in Medullary Thyroid Carcinoma. Thyroid, 1992, 2, 5-10.	4.5	41
262	Analysis of the lewisx epitope in human pancreas and pancreatic adenocarcinomas. International Journal of Gastrointestinal Cancer, 1992, 11, 125-35.	0.4	15
263	Nucleolar organizer regions in myogenic stromal tumours of the stomach. Virchows Archiv A, Pathological Anatomy and Histopathology, 1989, 415, 317-321.	1.4	20
264	Early myocardial lesions in mice with EMC virus myocarditis. Electrocardiographic and morphological findings. European Heart Journal, 1987, 8, 411-415.	2.2	3
265	Histological Alterations of the Preampullary Common Bile and Pancreatic Duct in Acute Biliary and Nonbiliary Pancreatitis. Digestion, 1986, 34, 93-100.	2.3	6
266	A program nucleus for encoding and decoding calendar dates. Computer Methods and Programs in Biomedicine, 1986, 23, 317-318.	4.7	0